Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Change in Account Payables (2016 - 2022)

Abeona Therapeutics has reported Change in Account Payables over the past 6 years, most recently at -$296000.0 for Q1 2022.

  • Quarterly results put Change in Account Payables at -$296000.0 for Q1 2022, down 120.86% from a year ago — trailing twelve months through Jun 2022 was -$19.6 million (down 372.82% YoY), and the annual figure for FY2024 was -$5.0 million, changed.
  • Change in Account Payables for Q1 2022 was -$296000.0 at Abeona Therapeutics, up from -$20.0 million in the prior quarter.
  • Over the last five years, Change in Account Payables for ABEO hit a ceiling of $4.5 million in Q3 2018 and a floor of -$20.0 million in Q4 2021.
  • Median Change in Account Payables over the past 3 years was $669000.0 (2021), compared with a mean of -$1.0 million.
  • Peak annual rise in Change in Account Payables hit 387.85% in 2018, while the deepest fall reached 176.69% in 2018.
  • Abeona Therapeutics' Change in Account Payables stood at -$273000.0 in 2018, then plummeted by 7226.01% to -$20.0 million in 2021, then surged by 98.52% to -$296000.0 in 2022.
  • The last three reported values for Change in Account Payables were -$296000.0 (Q1 2022), -$20.0 million (Q4 2021), and $669000.0 (Q3 2021) per Business Quant data.